Dkc 1 Ruse EOOD
- Address
- lock Available on a paid plan
Immune System Diseases
At Dkc 1 Ruse EOOD in Ruse, the clinical research in immune system diseases focuses on autoimmune conditions such as systemic lupus erythematosus and related forms of cutaneous lupus. These studies are designed to assess new treatment options and measure how well they reduce disease activity and improve control of ongoing symptoms.
- Systemic lupus erythematosus
- Subacute cutaneous lupus erythematosus
- Chronic cutaneous lupus erythematosus
The site is contributing to research that aims to improve both symptom control and longer-term treatment effectiveness for people living with complex autoimmune disease.
Musculoskeletal Diseases
Research in musculoskeletal diseases at this site includes studies in psoriatic arthritis, a condition that affects both the joints and the skin. The trials are exploring whether new therapies can better ease inflammation, reduce joint symptoms, and improve day-to-day function compared with existing approaches.
- Psoriatic arthritis
- Psoriatic Arthritis
This work reflects a broader effort to find more effective and better-tolerated treatments for chronic inflammatory joint disease.
Skin and Connective Tissue Diseases
The clinical trials in skin and connective tissue diseases are centered on lupus-related skin involvement, with a strong emphasis on evaluating therapies that may improve visible skin disease and overall patient outcomes. These studies are helping determine whether new medicines can offer better control for people whose disease has not responded well to standard treatment.
- Moderate to severe systemic lupus erythematosus
- Subacute Cutaneous Lupus Erythematosus
- Chronic Cutaneous Lupus Erythematosus
The research portfolio includes efforts to test new therapies, compare treatment effectiveness, and evaluate safety in patients with persistent autoimmune skin disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Biogen Idec Research Limited1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Biogen Idec Research Limited3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dkc 1 Ruse EOOD
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2) | Bristol-Myers Squibb Services Unlimited Company | Phase III | Not Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Litifilimab | 3 | Unknown | 2021-11-30 | 2023-02-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.